Skip to content

Nordic Nanovector appoints Fredrik Haavind as Head of Legal and Compliance

Oslo, Norway, 29 April 2019

Nordic Nanovector ASA (OSE: NANO) announces the appointment of Fredrik Haavind as the newly established Head of Legal and Compliance. Mr Haavind has 16 years of broad legal and compliance experience in Norwegian and International businesses, including international contracts law, governance and compliance, M&A, corporate and securities laws and regulations, with experience from in-house legal departments, law firms and the courts. He joins Nordic Nanovector from Fugro N.V., a global provider of geo-intelligence listed on Euronext, Amsterdam, where he acted as Head of Legal Europe.

Mr Haavind has a law degree from the University of Oslo, a degree in Business Administration from the Norwegian School of Management and an LL.M. – Master in International Business Law from King’s College, London.

Tone Kvåle, Nordic Nanovector CFO, said: “We welcome Fredrik to the team and value the experience and capabilities he brings as our legal and compliance requirements increase in parallel with the development of the business.”

Fredrik Haavind added: “I am very pleased to join Nordic Nanovector. The company is at an important juncture as it increases its pre-commercial activities and I am looking forward to supporting its further development.”

For further information, please contact:

IR enquiries

Malene Brondberg, VP Investor Relations and Corporate Communications

Cell: +44 7561 431 762


International Media Enquiries

Mark Swallow/David Dible (Citigate Dewe Rogerson)

Tel: +44 207 638 9571


About Nordic Nanovector

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers.

Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin’s lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.

Further information can be found at

Forward-looking statements

This press release contains certain forward-looking statements. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on Nordic Nanovector’s business, financial condition and results of operations. The terms “anticipates”, “assumes”, “believes”, “can”, “could”, “estimates”, “expects”, “forecasts”, “intends”, “may”, “might”, “plans”, “should”, “projects”, “targets”, “will”, “would” or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statements. These forward-looking statements are not historic facts. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in the forward-looking statements. Factors that could cause these differences include, but are not limited to, risks associated with implementation of Nordic Nanovector’s strategy, risks and uncertainties associated with the development and/or approval of Nordic Nanovector’s product candidates, ongoing and future clinical trials and expected trial results, the ability to commercialise Betalutin®, technology changes and new products in Nordic Nanovector’s potential market and industry, Nordic Nanovector’s freedom to operate (competitors patents) in respect of the products it develops, the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions, and legislative, regulatory and political factors. No assurance can be given that such expectations will prove to have been correct. Nordic Nanovector disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This information is subject to a duty of disclosure pursuant to Section 5-12 of the Securities Trading Act.

Source: Nordic Nanovector